# US 2023/0406843 A1 · Progranulin Modulators and Methods of Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406843 A1
- Document ID: US20230406843A1
- Status: Published application
- Kind: A1
- Application number: 18/038,749
- Filed: 2021-12-10
- Published: 2023-12-21
- Earliest claimed: 2020-12-10
- Assignees: Arkuda Therapeutics
- Applicants: Arkuda Therapeutics
- Inventors: Duane A. Burnett; James C. Lanter
- Web page: https://patentgrep.com/patent/US20230406843A1

## CPC

- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 405/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 493/08: Bridged systems
- C07D 498/04: Ortho-condensed systems
- C07D 498/08: Bridged systems
- C07D 498/10: Spiro-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).

## Claims

### Claim 1

A compound, or pharmaceutically acceptable salt thereof, having a structure of Formula (I):
wherein
ring A is a 4- to 12-membered heterocycle comprising a ring O or S atom, further comprising 0-3 additional ring heteroatoms selected from O, N, and S;
R1 is hydrogen, C1-6alkyl, halo, C1-3 haloalkyl, O—C1-3 haloalkyl,C1-3 alkylene-CN, C1-3 alkylene-NRN2, C0-6 alkylene-ORN, C0-6 alkylene- C(O)ORN, C0-6 alkylene-C(O)N(RN)2, or C0-6 alkylene-SOpRN; each RN is independently hydrogen or C1-6alkyl, and p is 0-2;
each R2 is independently halo;
each R3 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, C0-6alkylene-OH, C1-6alkoxy, C1-6 haloalkoxy, C1-6alkylene-O—C1-6alkyl, C0-6alkylene-NRaRb, S—C1-6alkyl, C2-6alkenyl, C(O)—C1-6haloalkyl, SO2—C1-6 alkyl, S2+(O)—(NRa)—C1-6alkyl, OR4, 5- to 8-membered heteroaryl comprising 1-4 ring N atoms, or 4- to 6-membered heterocycle comprising 1-4 ring heteroatoms selected from O, N, and S with at least 1 ring heteroatom being N, and the heteroaryl or heterocycle is optionally substituted with 1 or 2 substituents independently selected from halo, C1-6alkyl, OH, and C1-6alkoxy, or
two geminal R3 together with the atom to which they are attached form an oxo group, and
when ring A comprises a ring N atom, the N is substituted with Ra, and if ring A does not comprise a ring N atom, then at least one R3 is C0-6alkylene-NRaRb;
Ra and Rb are each independently hydrogen, C1-6alkyl, C1-6haloalkyl, C1-6alkylene-OH, C1-6alkylene-O—C1-6alkyl, C(O)—C1-6alkyl, C(O)—C1-6haloalkyl, S(O)2—C1-6alkyl, S(O)2—C1-6haloalkyl; or
Ra and Rb together with the nitrogen to which they are attached form a 3- to 12-membered monocyclic or bicyclic heterocycle optionally further comprising 1-3 additional ring heteroatoms selected from O, N, and S;
R4 is C2-6alkenyl, C2-6alkynyl, C0-6alkylene-C3-6cycloalkyl, or C0-6alkylene-C6-10aryl;
each Rd is independently H or D;
each Re is independently H, D, halo, OH, methyl, or methoxy, or
two geminal Re together with the atom to which they are attached form an oxo group or a spiro C3-5cycloalkyl;
m is 1-4; and
n is 0-2.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein ring A is a 4- to 6-membered heterocycle.

### Claim 3 (depends on 1, 2)

The compound or salt of claim 1 or 2, wherein ring A is a 6- to 8-membered heterocycle.

### Claim 4 (depends on 1, 2, 3)

The compound or salt of any one of claims 1 to 3, wherein ring A comprises a ring O atom and 0-3 additional ring heteroatoms selected from O, N, and S.

### Claim 5 (depends on 4)

The compound or salt of claim 4, wherein ring A comprises a tetrahydropyranyl ring.

### Claim 6 (depends on 1, 2, 3)

The compound or salt of any one of claims 1 to 3, wherein ring A comprises a ring 0 and N atom.

### Claim 7 (depends on 1, 2, 3)

The compound or salt of any one of claims 1 to 3, wherein ring A comprises a ring S atom and 0-3 additional ring heteroatoms selected from O, N, and S.

### Claim 8 (depends on 1, 2, 3)

The compound or salt of any one of claims 1 to 3, wherein ring A is
wherein * indicates the point of attachment of ring A to the adjacent carbonyl moiety of Formula I.

### Claim 9 (depends on 8)

The compound or salt of claim 8, wherein ring A is

### Claim 10 (depends on 8)

The compound or salt of claim 8, wherein ring A is

### Claim 11 (depends on 8)

The compound or salt of claim 8, wherein ring A is

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound or salt of any one of claims 1 to 11, wherein m is 1.

### Claim 13 (depends on 12)

The compound or salt of claim 12, wherein R3 is hydrogen.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound or salt of any one of claims 1 to 11, wherein m is 3.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound or salt of any one of claims 1 to 11, wherein m is 2.

### Claim 16 (depends on 15)

The compound or salt of claim 15, wherein ring A is

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16)

The compound or salt of any one of claims 1 to 12 and 14 to 16, wherein at least one R3 is C0-6alkylene-NRaRb.

### Claim 18 (depends on 17)

The compound or salt of claim 17, wherein at least one R3 is NH2.

### Claim 19 (depends on 17)

The compound or salt of claim 17, wherein at least one R3 is NHMe.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound or salt of any one of claims 1 to 12, and 14 to 19, wherein at least one R3 is halo.

### Claim 21 (depends on 20)

The compound or salt of claim 20, wherein at least one R3 is F.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21)

The compound or salt of any one of claims 1 to 12 and 14 to 21, wherein at least one R3 is C1-6alkoxy

### Claim 23 (depends on 22)

The compound or salt of claim 22, wherein at least one R3 is methoxy.

### Claim 24 (depends on 22)

The compound or salt of claim 22, wherein at least one R3 is ethoxy.

### Claim 25 (depends on 21)

The compound or salt of claim 21, wherein one R3 is F and one R3 is NH2.

### Claim 26 (depends on 23)

The compound or salt of claim 23, wherein one R3 is methoxy and one R3 is NH2.

### Claim 27 (depends on 23)

The compound or salt of claim 23, wherein one R3 is methoxy and one R3 is NHMe.

### Claim 28 (depends on 24)

The compound or salt of claim 24, wherein one R3 is ethoxy and one R3 is NH2.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound or salt of any one of claims 1 to 12, wherein R3 is S2+(O)—(NRa)—C1-6alkyl.

### Claim 30 (depends on 29)

The compound or salt of claim 29, wherein R3 is

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound or salt of any one of claims 1 to 12, wherein R3 is OR4.

### Claim 32 (depends on 31)

The compound or salt of claim 31, wherein R4 is C2-6alkynyl, C0-6alkylene-C3-6cycloalkyl, or C0-6alkylene-C6-10aryl.

### Claim 33 (depends on 33)

The compound or salt of claim 33, wherein R3 is

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound or salt of any one of claims 1 to 33, wherein n is 0.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound or salt of any one of claims 1 to 33, wherein n is 1.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound or salt of any one of claims 1 to 33, wherein n is 2.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 35, 36)

The compound or salt of any one of claims 1 to 28, 35 and 36, wherein R2 is F or Cl.

### Claim 38 (depends on 37)

The compound or salt of claim 37, wherein R2 is F.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound or salt of any one of claims 1 to 38, wherein R1 is halo.

### Claim 40 (depends on 39)

The compound or salt of claim 39, wherein R1 is F.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound or salt of any one of claims 1 to 38, wherein R1 is hydrogen.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound or salt of any one of claims 1 to 41, wherein at least one Rd is H.

### Claim 43 (depends on 42)

The compound or salt of claim 42, wherein each Rd is H.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound or salt of any one of claims 1 to 41, wherein at least wherein at least one Rd is D.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein at least one Re is H.

### Claim 46 (depends on 45)

The compound or salt of claim 45, wherein each Re is H.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein at least one Re is D.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein each Re is D.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein at least one Re is OH.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein at least one Re is halo.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein at least one Re is F.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein each Re is halo.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein each Re is F.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound or salt of any one of claims 1 to 44, wherein two geminal Re together with the atom to which they are attached form an oxo group.

### Claim 55

A compound, or pharmaceutically acceptable salt thereof, having a structure as shown in Table A.

### Claim 56 (depends on 55)

The compound or salt of claim 55, selected from compound 5605, 5602, 5599, 5575, 5564, 5550, 5472, 5545, 5543, 5461, 5267, 5448, 5475, 5087, 5077, 5051, 5045, 5042, 5021, and 5012, and pharmaceutically acceptable salts thereof.

### Claim 57 (depends on 56)

The compound or salt of claim 56, selected from compound 5599, 5564, 5472, 5077, and 5087, and pharmaceutically acceptable salts thereof.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound or salt of any one of claims 1 to 57 in the form of a salt.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A pharmaceutical composition comprising the compound or salt of any one of claims 1 to 58 and a pharmaceutically acceptable excipient.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

Use of the compound or salt of any one of claims 1 to 58 as a medicament for the modulation of progranulin.

### Claim 61 (depends on 60)

The use of claim 60, wherein progranulin secretion is increased.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of modulating progranulin in a subject in need thereof comprising administering to the subject the compound or salt of any one of claims 1 to 58 in an amount effective to increase the level of progranulin or granulin in the subject.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of treating a progranulin-associated disorder in a subject in need thereof comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject.

### Claim 64 (depends on 63)

The method of claim 63, wherein the progranulin-associated disorder is Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), Frontotemporal dementia-Granulin subtype (FTD-GRN), Lewy body dementia (LBD), Prion disease, Motor neuron diseases (MND), Huntington's disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA), a lysosomal storage disease, nephropathy, a disease associated with inclusions and/or misfunction of C9orf72, TDP-43, FUS, UBQLN2, VCP, CHMP28, and/or MAPT, an acute neurological disorder, glioblastoma, or neuroblastoma.

### Claim 65 (depends on 64)

The method of claim 64, wherein the Parkinson's disease is Parkinson's disease with GBA mutation.

### Claim 66 (depends on 64)

The method of claim 64, wherein the lysosomal storage disease is Paget's disease, Gaucher's disease, Nieman's Pick disease, Tay-Sachs Disease, Fabry Disease, Pompes disease, or Naso-Hakula disease.

### Claim 67 (depends on 64)

The method of claim 64, wherein the acute neurological disorder is stroke, cerebral hemorrhage, traumatic brain injury or head trauma.

### Claim 68 (depends on 64)

The method of claim 64, wherein the progranulin-associated disorder is Frontotemporal dementia (FTD).

### Claim 69 (depends on 64)

The method of claim 64, wherein the progranulin-associated disorder is Frontotemporal dementia-Granulin subtype (FTD-GRN).

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of increasing lysosomal protein levels in a cell comprising contacting the cell with an effective amount of the compound or salt of any one of claims 1 to 58.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of increasing lysosomal protein levels in a subject comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject.

### Claim 72 (depends on 70, 71)

The method of claim 70 or 71, wherein the lysosomal protein is progranulin, prosaposin, β-glucocerebrosidase, galactosidase alpha, cathepsin B, cathepsin Z, neuraminidase 1, tripeptidyl peptidase, alpha-L-fucosidase 2, mannosidase alpha class 2B member 2, mannosidase beta, serine carboxypeptidase 1, acid ceramidase, GM2 ganglioside activator, cathepsin D, cathepsin S, cathepsin K, cathepsin L, or hexosaminidase.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of treating a lysosomal storage disorder in a subject suffering therefrom comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject.

### Claim 74 (depends on 73)

The method of claim 73, wherein the lysosomal storage disorder is mucopolysaccharidosis, sphingolipidosis, glycogen storage disease type II, glycoprotein storage disease, Hurler disease, Scheie disease, Hunter disease, Sanfilippo disease A, Sanfilippo disease B, Sanfilippo disease C, Sanfilippo disease D, Morquio disease A, Morquio disease B, Maroteaux-Lamy disease, Sly disease, mucopolysaccharidosis type IX, mucopolysaccharidosis-plus syndrome, Fabry disease, Gaucher disease, Tay-Sachs disease, sialidosis, Niemann Pick type A, Niemann Pick type B, galactosialidosis, Niemann pick type C, I-cell disease, mucolipidosis type III, GM1 gangliosidosis, μ-galactosidase deficiency, α-mannosidosis, GM2 gangliosidosis, β-mannosidosis, Krabbe, fucosidosis, metachromatic leukodystrophy, aspartylglucosaminuria, multiple sulfatase deficiency, Schindler, Farber lipogranulomatosis, Pompe disease, Wolman disease, Danon disease, free sialic acid storage disease, ceroid lipofuscinosis, β-glucuronidase hypoactivity disease, Sandhoff disease, or cholesterol ester storage disease.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of treating an inflammatory disorder in a subject suffering therefrom comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject.

### Claim 76 (depends on 75)

The method of claim 75, wherein the inflammatory disorder is Sjogren disease, inflammatory arthritis, osteoarthritis, inflammatory bowel disease, or immune thrombocytopenia.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of treating a disorder in a subject suffering therefrom comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject, wherein the disorder is stroke, Down syndrome, congenital heart disease, diabetes, common variable immune deficiency (CVID), tubulo-interstitial kidney disease (TKD), polycystic liver disease, myocarditis, dermatitis hyperhomocysteinemia, endo-toxic shock, lung injury, bone defect (e.g., inflammatory periodontal bone defect), or osteolysis.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A method of treating a neurodegenerative disease in a subject suffering therefrom comprising administering a therapeutically effective amount of the compound or salt of any one of claims 1 to 58 to the subject.

### Claim 79 (depends on 78)

The method of claim 78, wherein the neurodegenerative disease is Parkinson's disease, frontotemporal dementia, Alzheimer's disease, Huntington's disease, traumatic brain injury, neuronal ceroid lipofuscinosis (NCL), multiple sclerosis, amyotrophic lateral sclerosis (ALS), aigyrophilic grain dementia, Alexander's disease, Alper's disease, cerebral palsy, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, HIV-associated dementia, lewy body dementia, Kennedy's disease, neuroborreliosis, primary lateral sclerosis, Refsum's disease, Gerstmann-Straussler-Scheinker disease, Hallevorden-Spatz disease, hereditary diffuse leukoencepholopathy with spheroids (HDLS), inclusion body myositis, multiple system atrophy, myotonic dystrophy, Nasu-Hakola disease, Schilder's disease, Wobbly Hedgehog Syndrome (WHS), Duchenne-Aran muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, HIV-associated neurocognitive disorder (HAND), tauopathy, chronic traumatic encephalopathy, or cerebellar downbeat nystagmus.
